Actualités Roche Holding Ag - 0QQ6 | Actions London Stock Exchange

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive...

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy Tecentriq Hybreza provides patients and...

Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation

Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation Switzerland’s most innovative research and...

Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen

Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen Das innovativste Forschungs...

Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis

Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with...

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH With the option to self-administer, PiaSky®...

Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak

Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak Roche is committed to supporting all those...

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) Approval is based on data from two Phase III studies in...

Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care

Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care The acquisition of...

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year...

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions Two-year Phase III data presented at ASRS 2024...

Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study...

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment...

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes The...

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) The FDA has approved updates to...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Roche Holding Ag (0QQ6)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

0QQ6 Actualités

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy

Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation

Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen

Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)

Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Roche Holding Ag (0QQ6) Actualités

Roche Holding Ag (0QQ6)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

0QQ6 Actualités

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy

Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation

Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen

Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)

Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application